NEW AMBRX BIOPHARMA INC(NASDAQ:AMAM) stock News

AMAM Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: Ambrx Biopharma Inc.

Ambrx Shareholders Approve Acquisition by Johnson & Johnson

2 years ago - By: InvestorPlace - Mentions: JNJ PEP HES CVX ...

3 Dividend Stocks That Are Too Good to Ignore: Q1 Edition

2 years ago - By: InvestorPlace - Mentions: SMCI KAMN

3 Stocks to Buy That Are Up 200% or More in 2024

2 years ago - By: InvestorPlace - Mentions: VKTX ADCT ACLX JNJ ...

The 3 Biotech Stocks That Could Make Your February Unforgettable

2 years ago - By: Benzinga

Looking Into Ambrx Biopharma's Recent Short Interest

2 years ago - By: Benzinga

Assessing Ambrx Biopharma: Insights From 7 Financial Analysts

2 years ago - By: Kahn Swick & Foti, LLC

AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM

2 years ago - By: The Motley Fool - Mentions: UNH JNJ KVUE

Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson

2 years ago - By: InvestorPlace - Mentions: JNJ

Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?

2 years ago - By: Brodsky & Smith LLC - Mentions: JNJ GRCL AZN AXNX ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

2 years ago - By: Investor's Business Daily - Mentions: NVDA TSLA JPM UNH ...

Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review

2 years ago - By: Kahn Swick & Foti, LLC

AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM

2 years ago - By: Seeking Alpha - Mentions: VKTX JPM SNDX BPMC ...

Barron’s cites cancer and weight loss plays for biotech M&A (NASDAQ:VKTX)

2 years ago - By: Bloomberg - Mentions: JNJ

Ambrx Holders Who Bought for Pennies See 6,700% Gain on J&J Bid

2 years ago - By: FN Media Group LLC - Mentions: ONCY ONC.CA AMGN ELEV ...

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

2 years ago - By: Brodsky & Smith LLC - Mentions: JNJ GRCL AZN AXNX ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

2 years ago - By: Investor's Business Daily - Mentions: JNJ MRK BSX HARP ...

J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value

2 years ago - By: Halper Sadeh LLC

AMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to Shareholders

2 years ago - By: Seeking Alpha - Mentions: JNJ

NEW AMBRX BIOPHARMA INC (AMAM) Stock News

AMAM Latest News, Press Relases and Analysis

Ambrx Shareholders Approve Acquisition by Johnson & Johnson

3 Dividend Stocks That Are Too Good to Ignore: Q1 Edition

3 Stocks to Buy That Are Up 200% or More in 2024

The 3 Biotech Stocks That Could Make Your February Unforgettable

Looking Into Ambrx Biopharma's Recent Short Interest

Assessing Ambrx Biopharma: Insights From 7 Financial Analysts

AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM

Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson

Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review

AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM

Barron’s cites cancer and weight loss plays for biotech M&A (NASDAQ:VKTX)

Ambrx Holders Who Bought for Pennies See 6,700% Gain on J&J Bid

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value

AMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to Shareholders

Johnson & Johnson to acquire Ambrx Biopharma (NYSE:JNJ)